It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The rising incidence of non-ST-segment elevation myocardial infarction (NSTEMI) and associated long-term high mortality constitutes an urgent clinical issue. Unfortunately, the study of possible interventions to treat this pathology lacks a reproducible pre-clinical model. Indeed, currently adopted small and large animal models of MI mimic only full-thickness, ST-segment-elevation (STEMI) infarcts, and hence cater only for an investigation into therapeutics and interventions directed at this subset of MI. Thus, we develop an ovine model of NSTEMI by ligating the myocardial muscle at precise intervals parallel to the left anterior descending coronary artery. Upon histological and functional investigation to validate the proposed model and comparison with STEMI full ligation model, RNA-seq and proteomics show the distinctive features of post-NSTEMI tissue remodelling. Transcriptome and proteome-derived pathway analyses at acute (7 days) and late (28 days) post-NSTEMI pinpoint specific alterations in cardiac post-ischaemic extracellular matrix. Together with the rise of well-known markers of inflammation and fibrosis, NSTEMI ischaemic regions show distinctive patterns of complex galactosylated and sialylated N-glycans in cellular membranes and extracellular matrix. Identifying such changes in molecular moieties accessible to infusible and intra-myocardial injectable drugs sheds light on developing targeted pharmacological solutions to contrast adverse fibrotic remodelling.
The study of the pathophysiology and possible interventions for non-ST-segment elevation myocardial infarction is hindered by the lack of a reproducible pre-clinical model. Here, authors develop an ovine model to reproduce post-ischemic remodeling in non-ST myocardial infarction and reveal distinct complex sugar moieties in cellular membranes and extracellular matrix patterns in infarcted tissue.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
















1 University of Galway, CÚRAM, SFI Research Centre for Medical Devices, Galway, Ireland; University of Padova, Department of Molecular Medicine, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
2 University of Galway, CÚRAM, SFI Research Centre for Medical Devices, Galway, Ireland (GRID:grid.5608.b)
3 Lithuanian University of Health Sciences, LSMU Biological Research Center, Kaunas, Lithuania (GRID:grid.45083.3a) (ISNI:0000 0004 0432 6841)
4 Lithuanian University of Health Sciences, Department of Cardiology, Medical Academy, Kaunas, Lithuania (GRID:grid.45083.3a) (ISNI:0000 0004 0432 6841); Lithuanian University of Health Sciences, Institute of Cardiology, Kaunas, Lithuania (GRID:grid.45083.3a) (ISNI:0000 0004 0432 6841)
5 University of Gothenburg, Proteomics Core Facility at Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)
6 University Paris Est Créteil, Glycobiology, Cell Growth and Tissue Repair Research Unit (Gly‑CRRET), Créteil, France (GRID:grid.410511.0) (ISNI:0000 0001 2149 7878)
7 University of Milano-Bicocca, Clinical Proteomics and Metabolomics Unit, School of Medicine and Surgery, Vedano al Lambro, Italy (GRID:grid.7563.7) (ISNI:0000 0001 2174 1754)
8 Lithuanian University of Health Sciences, Institute of Anatomy, Kaunas, Lithuania (GRID:grid.45083.3a) (ISNI:0000 0004 0432 6841); University of Auckland, Manaaki Manawa Centre for Heart Research, Department of Physiology, Faculty of Medical & Health Sciences, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343)
9 University of Padova, Department of Molecular Medicine, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
10 UF Health Heart and Vascular Hospital, Gainesville, USA (GRID:grid.430508.a) (ISNI:0000 0004 4911 114X)
11 University of Padova, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
12 University of Gothenburg, Proteomics Core Facility at Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); Oslo Metropolitan University, Section of Pharmacy, Department of Life Sciences and Health, Faculty of Health Sciences, Oslo, Norway (GRID:grid.412414.6) (ISNI:0000 0000 9151 4445)
13 University of Galway, CÚRAM, SFI Research Centre for Medical Devices, Galway, Ireland (GRID:grid.45083.3a)